Mark Titi, MD
Allergy & Immunology · Lancaster, PANPI 1649268525
Payments from drug & device makers
Across 287 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$908
- Mylan Specialty L.p.$399
- Boehringer Ingelheim$372
- Grifols USA, LLC$284
- Sunovion Pharmaceuticals Inc.$283
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$250%
- Food & beverage$5,14696%
- Education$1663%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 56 | $1,105 |
| GSK | 58 | $908 |
| Mylan Specialty L.p. | 20 | $399 |
| Boehringer Ingelheim | 29 | $372 |
| Grifols USA, LLC | 13 | $284 |
| Sunovion Pharmaceuticals Inc. | 18 | $283 |
| CSL Behring | 10 | $282 |
| Sanofi | 9 | $198 |
| Regeneron Healthcare Solutions, Inc. | 8 | $152 |
| Optinose US, Inc. | 7 | $147 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $114 |
| Biocryst US Sales Co., LLC | 4 | $102 |
| Novartis | 4 | $98 |
| Actelion Pharmaceuticals US, Inc. | 6 | $92 |
| Sanofi-aventis U.S. LLC | 1 | $85 |
| Genentech USA, Inc. | 5 | $82 |
| Pfizer | 3 | $70 |
| Viatris Specialty LLC | 3 | $64 |
| Shire North American Group Inc | 4 | $61 |
| Pharming Healthcare, Inc. | 2 | $54 |
| Insmed, Inc. | 3 | $44 |
| Alk-abello, Inc | 3 | $41 |
| Vanda Pharmaceuticals Inc. | 2 | $39 |
| AbbVie | 1 | $33 |
| Kaleo, Inc. | 2 | $32 |
| Aimmune Therapeutics, Inc. | 1 | $27 |
| Paratek Pharmaceuticals, Inc. | 1 | $26 |
| Merck | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Philips North America LLC | 2 | $23 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
| Resmed Corp | 2 | $22 |
| Galderma Laboratories, L.p. | 1 | $18 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,337 in reported general payments places this provider in the 60th percentile of 175 allergy & immunology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 11 | $209,172 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $18,986 |
| Advair HfaFluticasone Propion/Salmeterol | 31 | $17,119 |
| Arnuity ElliptaFluticasone Furoate | 27 | $14,382 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $10,079 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 34 | $7,536 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $6,600 |
| DuleraMometasone/Formoterol | 13 | $5,232 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,141 |
| Epinephrine | 24 | $3,912 |
| Azelastine Hcl | 119 | $3,296 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $2,138 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 60 | $1,801 |
| Mometasone Furoate | 14 | $1,471 |
| Ipratropium Bromide | 24 | $908 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $282 | $209,17211 claims |
| GSKBreo Ellipta, Arnuity Ellipta, Trelegy Ellipta, Anoro Ellipta | $908 | $48,58883 claims |
| AstraZenecaSymbicort | $1,105 | $6,60027 claims |
| MerckDulera | $24 | $5,23213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 175 allergy & immunology providers in Pennsylvania.
Other allergy & immunology in Lancaster
- Drew WeissmanPhiladelphia$15.3M
- Timothy CraigHershey$2M
- Eric SchenkelBethlehem$845K
- Sergei BelenkyPittsburgh$775K
- Sandra GawchikUpland$390K
- Anthony RooklinGlen Mills$319K
- Corinna BowserNarberth$229K
- Thomas KleinHavertown$222K
- Rahul DattaPhiladelphia$198K
- Shailen ShahCollegeville$183K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.